Monitor for regulatory engagement updates on VMT-α-NET registration pathway and late-2026 data readouts across all three clinical programs. The $271M cash runway into late 2027 provides a long no-dilution window, but the widening loss trajectory without revenue growth keeps the stock in a show-me phase until pivotal data emerges.
Price Chart
Executive Summary
Perspective Therapeutics reported Q1 2026 results with a net loss of $26.2M ($0.25/share), widening from $18.2M loss in Q1 2025. The company ended the quarter with $271M in cash, up from $145M at year-end 2025, following a $164M underwritten offering in February 2026. Clinical programs are advancing with multiple data readouts expected in late 2026, but the widening loss and lack of revenue growth are negatives for a pre-commercial biotech.
Key Financial Metrics
Key Facts
- Net loss of $26.2M for Q1 2026 vs $18.2M in Q1 2025, a 44% increase in losses
- Cash, cash equivalents, and short-term investments of $271M as of March 31, 2026, up from $145M at December 31, 2025
- February 2026 underwritten offering raised net proceeds of approximately $164M, issuing 39.6M shares and pre-funded warrants for 6.6M shares
- Research and development expenses increased 50% to $21.4M from $14.3M year-over-year
- Cash runway expected into late 2027 to support clinical milestones and operational investments
- Lead program VMT-α-NET advancing toward a registration-enabling study with regulatory engagement expected in 2026
- Cohort 4 of VMT-α-NET study now open for recruitment; Cohort 3 closed with 20 patients treated
- Chicago manufacturing site on track to complete construction in 2026
Financial Impact
Net loss widened by $8.0M YoY to $26.2M; cash position strengthened by $126M to $271M via $164M equity offering
Risk Factors
- Widening net loss with no revenue stream to offset operating expenses
- Clinical trial execution risk across three early-stage programs
- Dilution risk from potential future capital raises if cash burn accelerates
- Regulatory pathway uncertainty for VMT-α-NET registration-enabling study
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-216777 |
| Document: catx-20260511.htm | 0001193125-26-216777 |
| Document: catx-ex99_2.htm | 0001193125-26-216777 |
| Document: 0001193125-26-216777-index-headers.html | 0001193125-26-216777 |
| Document: 0001193125-26-216777-index.html | 0001193125-26-216777 |
| Document: 0001193125-26-216777.txt | 0001193125-26-216777 |
| 8-K Data (Synthetic) | 0001193125-26-216777 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $1.61 | awaiting T+20 | — | $1.21 (−25.16%) |
Oct 8, 2026 19d ago | 8-K | $2.71 | awaiting T+20 | — | $1.21 (−55.54%) |
Oct 2, 2026 25d ago | Press Release | $2.76 | awaiting T+20 | — | $1.21 (−56.34%) |
Sep 14, 2026 6w ago | 8-K | $2.92 $2.52 | ▼ −13.70% | ▼ −15.96% | $1.21 (−58.73%) |
Sep 11, 2026 6w ago | Press Release | $2.81 $2.66 | ▼ −5.34% | ▼ −7.21% | $1.21 (−57.12%) |
Sep 8, 2026 6w ago | Insider Cluster | $2.99 $2.46 | ▼ −17.73% | ▼ −19.67% | $1.21 (−59.70%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.21 (−61.38%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.21 (−61.38%) |
Aug 10, 2026 11w ago | 8-K | $3.18 $2.99 | ▼ −5.97% | ▼ −4.92% | $1.21 (−62.11%) |
Jul 17, 2026 14w ago | Press Release | $2.99 $3.20 | ▲ +7.02% | ▲ +2.58% | $1.21 (−59.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers